Related Experiment Videos
Molecular epidemiology of hepatitis C virus infection in dialysis patients
F Fabrizi1, G Lunghi, B Pagliari
1Nephrology and Dialysis Division, Lecco Hospital, Italy.
Insights
Hepatitis C virus (HCV) genotype 2a is dominant in Italian dialysis patients. Antibody responses to HCV proteins differ by genotype, highlighting the clinical utility of HCV genotyping in nephrology.
Area of Science:
- Virology
- Nephrology
- Immunology
Background:
- Limited molecular data exists for hepatitis C virus (HCV) in dialysis patients.
- Understanding HCV genotypes and immune responses in this population is crucial for clinical management.
Purpose of the Study:
- To investigate the molecular biology of HCV infection in dialysis patients.
- To determine HCV genotypes and analyze antibody responses in relation to viral strains.
- To assess the utility of HCV genotyping in routine nephrology care.
Main Methods:
- Analysis of 101 dialysis patients using RT-PCR for HCV viremia and line probe assay for genotyping.
- Serological analysis to detect type-specific antibodies against HCV antigens (c33-c, c100-3, 5-1-1, NS-3, NS-4).
- Comparison of genotyping results with clinical and demographic data.
Main Results:
- HCV RNA detected in 60% of patients; genotype 2a was dominant (57%), followed by genotype 1b (37%).
- No correlation found between HCV genotype and patient demographics or clinical features.
- Higher antibody response to specific antigens (c33-c, c100-3, 5-1-1, NS-3, NS-4) observed in genotype 1b infections compared to genotype 2a.
- High agreement (82%) between RT-PCR genotyping and serological antibody detection.
Conclusions:
- Hepatitis C virus subtype 2a is prevalent in Italian dialysis patients.
- Antibody responses to HCV proteins are genotype-dependent.
- HCV genotyping is valuable for nephrologists managing dialysis patients due to potential biological differences among strains.
Abstract:
There are very few data on the molecular biology of hepatitis C virus (HCV) infection in dialysis patients. 101 patients undergoing dialysis treatment in 4 units in the Lombardy, northern Italy, were analyzed by RT-PCR for HCV viremia, by line probe assay technology for HCV genotyping and by a serological analysis for detecting type-specific antibodies. 61 of 101 (60%) patients showed detectable HCV RNA in serum; HCV genotype 2a was dominant (30/53 = 57%), followed by HCV genotype 1b (20/53 = 37%). There was no relationship between HCV genotyping and the clinical or demographic features of the patients. The antibody response toward the c33-c, c100-3, and 5-1-1 antigens was more frequent in HCV genotype 1b compared with genotype 2a (p = 0.046, p = 0.001 and p = 0.0001, respectively). The antibody levels to NS-3 and NS-4 HCV proteins were significantly higher in patients with-HCV genotype 1b in comparison with HCV 2a-infected individuals (p = 0.0001). There was a high level (82%) of agreement between HCV genotyping by RT-PCR and the assessment of type-specific antibodies by serological analysis; further, it was possible to detect type-specific antibodies in 6 of 22 (27%) patients in whom PCR amplification was unsuccessful. In conclusion, HCV subtype 2a was dominant in our population of HCV-infected dialysis patients, dialysis patients infected by different genotypes showed similar demographic and clinical characteristics, the antibody response toward the NS-3- and NS-4-related antigen of HCV was genotype dependent. There was a high level of agreement between HCV genotyping by RT-PCR and the detection of type-specific antibodies by serological analysis. As significant biological differences may exist among HCV strains, the assessment of HCV types may be very useful in the routine clinical activity of nephrologists in dialysis units.